Advertisement

Thyroid Status and Outcomes in Kidney Disease

  • Connie M. RheeEmail author
  • Gregory A. Brent
  • Kamyar Kalantar-Zadeh
Chapter

Abstract

Thyroid dysfunction is a common yet under-recognized complication among chronic kidney disease (CKD) patients, including those with end-stage renal disease (ESRD) receiving treatment with dialysis [1, 2]. While comparatively greater focus has been placed upon other endocrine derangements in kidney disease, such as diabetes and secondary hyperparathyroidism, population-based studies have shown that advanced CKD and ESRD patients have a higher prevalence of hypothyroidism compared to the general population [3–10]. Despite this disproportionate burden, hypothyroidism may be frequently overlooked in dialysis patients, possibly due to overlap of its accompanying signs and symptoms with those of uremia (e.g., fatigue, depression, reduced cognition, impaired physical function), as well as attribution of thyroid function test changes to underlying illness rather than primary thyroid disease [1, 2].

Keywords

Thyroid Hypothyroidism Hyperthyroidism Chronic kidney disease End-stage renal disease Dialysis Mortality Cardiovascular disease Health-related quality of life 

References

  1. 1.
    Rhee CM. The interaction between thyroid and kidney disease: an overview of the evidence. Curr Opin Endocrinol Diabetes Obes. 2016;23(5):407–15.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Rhee CM, Brent GA, Kovesdy CP, et al. Thyroid functional disease: an under-recognized cardiovascular risk factor in kidney disease patients. Nephrol Dial Transplant. 2015;30(5):724–37.PubMedCrossRefGoogle Scholar
  3. 3.
    Kutlay S, Atli T, Koseogullari O, Nergizoglu G, Duman N, Gullu S. Thyroid disorders in hemodialysis patients in an iodine-deficient community. Artif Organs. 2005;29(4):329–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Lo JC, Chertow GM, Go AS, Hsu CY. Increased prevalence of subclinical and clinical hypothyroidism in persons with chronic kidney disease. Kidney Int. 2005;67(3):1047–52.PubMedCrossRefGoogle Scholar
  5. 5.
    Rhee CM, Alexander EK, Bhan I, Brunelli SM. Hypothyroidism and mortality among dialysis patients. Clin J Am Soc Nephrol: CJASN. 2013;8(4):593–601.PubMedCrossRefGoogle Scholar
  6. 6.
    Rhee CM, Kalantar-Zadeh K, Streja E, et al. The relationship between thyroid function and estimated glomerular filtration rate in patients with chronic kidney disease. Nephrol Dial Transplant. 2015;30(2):282–7.PubMedCrossRefGoogle Scholar
  7. 7.
    Rhee CM, Kim S, Gillen DL, et al. Association of thyroid functional disease with mortality in a national cohort of incident hemodialysis patients. J Clin Endocrinol Metab. 2015;100(4):1386–95.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Rhee CM, Ravel VA, Streja E, et al. Thyroid functional disease and mortality in a national peritoneal dialysis cohort. J Clin Endocrinol Metab. 2016;101(11):4054–61.PubMedPubMedCentralCrossRefGoogle Scholar
  9. 9.
    Rhee CM, You AS, Nguyen DV, et al. Thyroid status and mortality in a prospective hemodialysis cohort. J Clin Endocrinol Metab. 2017;102(5):1568–77.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Shantha GP, Kumar AA, Bhise V, Khanna R, Sivagnanam K, Subramanian KK. Prevalence of subclinical hypothyroidism in patients with end-stage renal disease and the role of serum albumin: a cross-sectional study from South India. Cardiorenal Med. 2011;1(4):255–60.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Ladenson PW. Diagnosis of hypothyroidism. In: Braverman LE, Philadelphia CDS, editors. Werner and Ingbar's the thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. p. 606–11.Google Scholar
  12. 12.
    Hollowell JG, Staehling NW, Flanders WD, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002;87(2):489–99.PubMedCrossRefGoogle Scholar
  13. 13.
    Lin CC, Chen TW, Ng YY, Chou YH, Yang WC. Thyroid dysfunction and nodular goiter in hemodialysis and peritoneal dialysis patients. Perit Dial Int. 1998;18(5):516–21.PubMedGoogle Scholar
  14. 14.
    Canavan JP, Holt J, Easton J, Smith K, Goldspink DF. Thyroid-induced changes in the growth of the liver, kidney, and diaphragm of neonatal rats. J Cell Physiol. 1994;161(1):49–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Slotkin TA, Seidler FJ, Kavlock RJ, Bartolome JV. Thyroid hormone differentially regulates cellular development in neonatal rat heart and kidney. Teratology. 1992;45(3):303–12.PubMedCrossRefGoogle Scholar
  16. 16.
    Bentley AG, Madsen KM, Davis RG, Tisher CC. Response of the medullary thick ascending limb to hypothyroidism in the rat. Am J Pathol. 1985;120(2):215–21.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Salomon MI, Di Scala V, Grishman E, Brener J, Churg J. Renal lesions in hypothyroidism: a study based on kidney biopsies. Metab Clin Exp. 1967;16(9):846–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Bradley SE, Coelho JB, Sealey JE, Edwards KD, Stephan F. Changes in glomerulotubular dimensions, single nephron glomerular filtration rates and the renin-angiotensin system in hypothyroid rats. Life Sci. 1982;30(7–8):633–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Rodriguez-Gomez I, Banegas I, Wangensteen R, et al. Influence of thyroid state on cardiac and renal capillary density and glomerular morphology in rats. J Endocrinol. 2013;216(1):43–51.PubMedCrossRefGoogle Scholar
  20. 20.
    Wheatley T, Edwards OM. Mild hypothyroidism and oedema: evidence for increased capillary permeability to protein. Clin Endocrinol. 1983;18(6):627–35.CrossRefGoogle Scholar
  21. 21.
    Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system. N Engl J Med. 2001;344(7):501–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Mariani LH, Berns JS. The renal manifestations of thyroid disease. J Am Soc Nephrol: JASN. 2012;23(1):22–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Basu G, Mohapatra A. Interactions between thyroid disorders and kidney disease. Indian J Endocrinol Metab. 2012;16(2):204–13.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Vargas F, Moreno JM, Rodriguez-Gomez I, et al. Vascular and renal function in experimental thyroid disorders. Eur J Endocrinol/Eur Fed Endocr Soc. 2006;154(2):197–212.CrossRefGoogle Scholar
  25. 25.
    Bradley SE, Stephan F, Coelho JB, Reville P. The thyroid and the kidney. Kidney Int. 1974;6(5):346–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Falk SA, Buric V, Hammond WS, Conger JD. Serial glomerular and tubular dynamics in thyroidectomized rats with remnant kidneys. Am J Kidney Dis. 1991;17(2):218–27.PubMedCrossRefGoogle Scholar
  27. 27.
    Karanikas G, Schutz M, Szabo M, et al. Isotopic renal function studies in severe hypothyroidism and after thyroid hormone replacement therapy. Am J Nephrol. 2004;24(1):41–5.PubMedCrossRefGoogle Scholar
  28. 28.
    Kreisman SH, Hennessey JV. Consistent reversible elevations of serum creatinine levels in severe hypothyroidism. Arch Intern Med. 1999;159(1):79–82.PubMedCrossRefGoogle Scholar
  29. 29.
    Villabona C, Sahun M, Roca M, et al. Blood volumes and renal function in overt and subclinical primary hypothyroidism. Am J Med Sci. 1999;318(4):277–80.PubMedCrossRefGoogle Scholar
  30. 30.
    Asvold BO, Bjoro T, Vatten LJ. Association of thyroid function with estimated glomerular filtration rate in a population-based study: the HUNT study. European J Endocrinol/Eur Fed Endocr Soc. 2011;164(1):101–5.CrossRefGoogle Scholar
  31. 31.
    Chonchol M, Lippi G, Salvagno G, Zoppini G, Muggeo M, Targher G. Prevalence of subclinical hypothyroidism in patients with chronic kidney disease. Clin J Am Soc Nephrol: CJASN. 2008;3(5):1296–300.PubMedCrossRefGoogle Scholar
  32. 32.
    Lippi G, Montagnana M, Targher G, Salvagno GL, Guidi GC. Relationship between thyroid status and renal function in a general population of unselected outpatients. Clin Biochem. 2008;41(7–8):625–7.PubMedCrossRefGoogle Scholar
  33. 33.
    Meuwese CL, Gussekloo J, de Craen AJ, Dekker FW, den Elzen WP. Thyroid status and renal function in older persons in the general population. J Clin Endocrinol Metab. 2014;99(8):2689–96.PubMedCrossRefGoogle Scholar
  34. 34.
    Targher G, Chonchol M, Zoppini G, et al. Prevalence of thyroid autoimmunity and subclinical hypothyroidism in persons with chronic kidney disease not requiring chronic dialysis. Clin Chem Lab Med. 2009;47(11):1367–71.PubMedCrossRefGoogle Scholar
  35. 35.
    Woodward A, McCann S, Al-Jubouri M. The relationship between estimated glomerular filtration rate and thyroid function: an observational study. Ann Clin Biochem. 2008;45.(Pt 5:515–7.PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang Y, Chang Y, Ryu S, et al. Thyroid hormone levels and incident chronic kidney disease in euthyroid individuals: the Kangbuk Samsung Health Study. Int J Epidemiol. 2014;43(5):1624–32.PubMedCrossRefGoogle Scholar
  37. 37.
    Shin DH, Lee MJ, Kim SJ, et al. Preservation of renal function by thyroid hormone replacement therapy in chronic kidney disease patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 2012;97(8):2732–40.PubMedCrossRefGoogle Scholar
  38. 38.
    Wiederkehr MR, Kalogiros J, Krapf R. Correction of metabolic acidosis improves thyroid and growth hormone axes in haemodialysis patients. Nephrol Dial Transplant. 2004;19(5):1190–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Napolitano G, Bonomini M, Bomba G, et al. Thyroid function and plasma selenium in chronic uremic patients on hemodialysis treatment. Biol Trace Elem Res. 1996;55(3):221–30.PubMedCrossRefGoogle Scholar
  40. 40.
    Schomburg L. Selenium, selenoproteins and the thyroid gland: interactions in health and disease. Nat Rev Endocrinol. 2011;8(3):160–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Sanai T, Inoue T, Okamura K, et al. Reversible primary hypothyroidism in Japanese patients undergoing maintenance hemodialysis. Clin Nephrol. 2008;69(2):107–13.PubMedCrossRefGoogle Scholar
  42. 42.
    Takeda S, Michigishi T, Takazakura E. Iodine-induced hypothyroidism in patients on regular dialysis treatment. Nephron. 1993;65(1):51–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Brough R, Jones C. Iatrogenic iodine as a cause of hypothyroidism in infants with end-stage renal failure. Pediatr Nephrol. 2006;21(3):400–2.PubMedCrossRefGoogle Scholar
  44. 44.
    Lee SY, Rhee CM, Leung AM, Braverman LE, Brent GA, Pearce EN. A review: radiographic iodinated contrast media-induced thyroid dysfunction. J Clin Endocrinol Metab. 2015;100(2):376–83.PubMedCrossRefGoogle Scholar
  45. 45.
    Moisey RS, McPherson S, Wright M, Orme SM. Thyroiditis and iodide mumps following an angioplasty. Nephrol Dial Transplant. 2007;22(4):1250–2.PubMedCrossRefGoogle Scholar
  46. 46.
    Rhee CM, Bhan I, Alexander EK, Brunelli SM. Association between iodinated contrast media exposure and incident hyperthyroidism and hypothyroidism. Arch Intern Med. 2012;172(2):153–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Soldin OP. Measuring serum thyroid-stimulating hormone, thyroid hormones, thyroid-directed antibodies, and transport proteins. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s the thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. p. 279–97.Google Scholar
  48. 48.
    Feinstein EI, Kaptein EM, Nicoloff JT, Massry SG. Thyroid function in patients with nephrotic syndrome and normal renal function. Am J Nephrol. 1982;2(2):70–6.PubMedCrossRefGoogle Scholar
  49. 49.
    Gilles R, den Heijer M, Ross AH, Sweep FC, Hermus AR, Wetzels JF. Thyroid function in patients with proteinuria. Neth J Med. 2008;66(11):483–5.PubMedGoogle Scholar
  50. 50.
    Langton JE, Brent GA. Nonthyroidal illness syndrome: evaluation of thyroid function in sick patients. Endocrinol Metab Clin N Am. 2002;31(1):159–72.CrossRefGoogle Scholar
  51. 51.
    Klein I. In: Bonow RO, Mann DL, Zipes DP, Libby P, editors. Braunwald’s heart disease. 9th ed. Philadelphia: Elsevier Saunders; 2012. p. 1829–43.Google Scholar
  52. 52.
    Imai T, Hirata Y, Iwashina M, Marumo F. Hormonal regulation of rat adrenomedullin gene in vasculature. Endocrinology. 1995;136(4):1544–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Taddei S, Caraccio N, Virdis A, et al. Impaired endothelium-dependent vasodilatation in subclinical hypothyroidism: beneficial effect of levothyroxine therapy. J Clin Endocrinol Metab. 2003;88(8):3731–7.PubMedCrossRefGoogle Scholar
  54. 54.
    Hak AE, Pols HA, Visser TJ, Drexhage HA, Hofman A, Witteman JC. Subclinical hypothyroidism is an independent risk factor for atherosclerosis and myocardial infarction in elderly women: the Rotterdam Study. Ann Intern Med. 2000;132(4):270–8.PubMedCrossRefGoogle Scholar
  55. 55.
    Rhee CM, Budoff MJ, Novoa A, You AS, Nakata T, Nguyen DV, Brent GA, Kalantar-Zadeh K. Thyroid status: a novel coronary artery calcification risk factor in hemodialysis patients. Abstract submitted to the 2018 American Heart Association Scientific Session.Google Scholar
  56. 56.
    Meuwese CL, Carrero JJ, Cabezas-Rodriguez I, et al. Nonthyroidal illness: a risk factor for coronary calcification and arterial stiffness in patients undergoing peritoneal dialysis? J Intern Med. 2013;274(6):584–93.PubMedCrossRefGoogle Scholar
  57. 57.
    Meuwese CL, Olauson H, Qureshi AR, et al. Associations between thyroid hormones, calcification inhibitor levels and vascular calcification in end-stage renal disease. PLoS One. 2015;10(7):e0132353.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001;86(2):732–7.PubMedCrossRefGoogle Scholar
  59. 59.
    Donati RM, Fletcher JW, Warnecke MA, Gallagher NI. Erythropoiesis in hypothyroidism. Proc Soc Exp Biol Med. 1973;144(1):78–82.PubMedCrossRefGoogle Scholar
  60. 60.
    Erdogan M, Kosenli A, Ganidagli S, Kulaksizoglu M. Characteristics of anemia in subclinical and overt hypothyroid patients. Endocr J. 2012;59(3):213–20.PubMedCrossRefGoogle Scholar
  61. 61.
    Fein HG, Rivlin RS. Anemia in thyroid diseases. Med Clin North Am. 1975;59(5):1133–45.PubMedCrossRefGoogle Scholar
  62. 62.
    Ng YY, Lin HD, Wu SC, et al. Impact of thyroid dysfunction on erythropoietin dosage in hemodialysis patients. Thyroid. 2013;23(5):552–61.PubMedCrossRefGoogle Scholar
  63. 63.
    Coban E, Yazicioglu G, Ozdogan M. Platelet activation in subjects with subclinical hypothyroidism. Med Sci Monit. 2007;13(4):CR211–4.PubMedGoogle Scholar
  64. 64.
    Kim JH, Park JH, Kim SY, Bae HY. The mean platelet volume is positively correlated with serum thyrotropin concentrations in a population of healthy subjects and subjects with unsuspected subclinical hypothyroidism. Thyroid. 2013;23(1):31–7.PubMedCrossRefGoogle Scholar
  65. 65.
    Masunaga R, Nagasaka A, Nakai A, et al. Alteration of platelet aggregation in patients with thyroid disorders. Metab Clin Exp. 1997;46(10):1128–31.PubMedCrossRefGoogle Scholar
  66. 66.
    Yilmaz H, Ertugrul O, Ertugrul B, Ertugrul D. Mean platelet volume in patients with subclinical hypothyroidism. Platelets. 2011;22(2):143–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304(12):1365–74.PubMedPubMedCentralCrossRefGoogle Scholar
  68. 68.
    Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation. 2012;126(9):1040–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Rhee CM, Curhan GC, Alexander EK, Bhan I, Brunelli SM. Subclinical hypothyroidism and survival: the effects of heart failure and race. J Clin Endocrinol Metab. 2013;98(6):2326–36.PubMedPubMedCentralCrossRefGoogle Scholar
  70. 70.
    Ro K, Yuen AD, Du L, et al. The impact of hypothyroidism and heart failure on hospitalization risk. Thyroid. 2018.Google Scholar
  71. 71.
    United States Renal Data System. USRDS 2017 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda; 2017.Google Scholar
  72. 72.
    Lim VS. Thyroid function in patients with chronic renal failure. Am J Kidney Dis. 2001;38(4 Suppl 1):S80–4.PubMedCrossRefGoogle Scholar
  73. 73.
    Jaroszynski AJ, Glowniak A, Chrapko B, et al. Low-T3 syndrome and signal-averaged ECG in haemodialysed patients. Physiol Res/Academia Scientiarum Bohemoslovaca. 2005;54(5):521–6.Google Scholar
  74. 74.
    Zoccali C, Benedetto F, Mallamaci F, et al. Low triiodothyronine and cardiomyopathy in patients with end-stage renal disease. J Hypertens. 2006;24(10):2039–46.PubMedCrossRefGoogle Scholar
  75. 75.
    Tatar E, Sezis Demirci M, Kircelli F, et al. The association between thyroid hormones and arterial stiffness in peritoneal dialysis patients. Int Urol Nephrol. 2012;44(2):601–6.PubMedCrossRefGoogle Scholar
  76. 76.
    Tatar E, Kircelli F, Asci G, et al. Associations of triiodothyronine levels with carotid atherosclerosis and arterial stiffness in hemodialysis patients. Clin J Am Soc Nephrol: CJASN. 2011;6(9):2240–6.PubMedCrossRefGoogle Scholar
  77. 77.
    Yilmaz MI, Sonmez A, Karaman M, et al. Low triiodothyronine alters flow-mediated vasodilatation in advanced nondiabetic kidney disease. Am J Nephrol. 2011;33(1):25–32.PubMedCrossRefGoogle Scholar
  78. 78.
    Zoccali C, Mallamaci F, Tripepi G, Cutrupi S, Pizzini P. Low triiodothyronine and survival in end-stage renal disease. Kidney Int. 2006;70(3):523–8.PubMedCrossRefGoogle Scholar
  79. 79.
    Enia G, Panuccio V, Cutrupi S, et al. Subclinical hypothyroidism is linked to micro-inflammation and predicts death in continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant. 2007;22(2):538–44.PubMedCrossRefGoogle Scholar
  80. 80.
    Carrero JJ, Qureshi AR, Axelsson J, et al. Clinical and biochemical implications of low thyroid hormone levels (total and free forms) in euthyroid patients with chronic kidney disease. J Intern Med. 2007;262(6):690–701.PubMedCrossRefGoogle Scholar
  81. 81.
    Fernandez-Reyes MJ, Diez JJ, Collado A, et al. Are low concentrations of serum triiodothyronine a good marker for long-term mortality in hemodialysis patients? Clin Nephrol. 2010;73(3):238–40.PubMedCrossRefGoogle Scholar
  82. 82.
    Ozen KP, Asci G, Gungor O, et al. Nutritional state alters the association between free triiodothyronine levels and mortality in hemodialysis patients. Am J Nephrol. 2011;33(4):305–12.PubMedCrossRefGoogle Scholar
  83. 83.
    Horacek J, Dusilova Sulkova S, Kubisova M, et al. Thyroid hormone abnormalities in hemodialyzed patients: low triiodothyronine as well as high reverse triiodothyronine are associated with increased mortality. Physiol Res/Academia Scientiarum Bohemoslovaca. 2012;61(5):495–501.Google Scholar
  84. 84.
    Lin YC, Lin YC, Chen TW, Yang WC, Lin CC. Abnormal thyroid function predicts mortality in patients receiving long-term peritoneal dialysis: a case-controlled longitudinal study. J Chin Med Assoc. 2012;75(2):54–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Meuwese CL, Dekker FW, Lindholm B, et al. Baseline levels and trimestral variation of triiodothyronine and thyroxine and their association with mortality in maintenance hemodialysis patients. Clin J Am Soc Nephrol: CJASN. 2012;7(1):131–8.PubMedCrossRefGoogle Scholar
  86. 86.
    Yang JW, Han ST, Song SH, et al. Serum T3 level can predict cardiovascular events and all-cause mortality rates in CKD patients with proteinuria. Ren Fail. 2012;34(3):364–72.PubMedCrossRefGoogle Scholar
  87. 87.
    Chang TI, Nam JY, Shin SK, Kang EW. Low triiodothyronine syndrome and long-term cardiovascular outcome in incident peritoneal Dialysis patients. Clin J Am Soc Nephrol: CJASN. 2015;10(6):975–82.PubMedCrossRefGoogle Scholar
  88. 88.
    Wiersinga WM, Van den Berghe G. Nonthyroidal illness syndrome. In: Braverman LE, Cooper DS, editors. Werner and Ingbar’s the thyroid. 10th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. p. 203–16.Google Scholar
  89. 89.
    Meuwese CL, Dekkers OM, Stenvinkel P, Dekker FW, Carrero JJ. Nonthyroidal illness and the cardiorenal syndrome. Nat Rev Nephrol. 2013;9(10):599–609.PubMedCrossRefGoogle Scholar
  90. 90.
    Carrero JJ, Stenvinkel P, Lindholm B. Endocrine aspects of chronic kidney disease. In: Taal MW, Chertow GM, Marsden PA, Skorecki K, Yu AS, Brenner BM, editors. Taal Brenner and Rector’s the kidney. 9th ed. Philadelphia: Elsevier Saunders; 2012. p. 2122–37.Google Scholar
  91. 91.
    Kaptein EM. Thyroid hormone metabolism and thyroid diseases in chronic renal failure. Endocr Rev. 1996;17(1):45–63.PubMedCrossRefGoogle Scholar
  92. 92.
    Kang EW, Nam JY, Yoo TH, et al. Clinical implications of subclinical hypothyroidism in continuous ambulatory peritoneal dialysis patients. Am J Nephrol. 2008;28(6):908–13.PubMedCrossRefGoogle Scholar
  93. 93.
    Drechsler C, Schneider A, Gutjahr-Lengsfeld L, et al. Thyroid function, cardiovascular events, and mortality in diabetic hemodialysis patients. Am J Kidney Dis. 2014;63(6):988–96.PubMedCrossRefGoogle Scholar
  94. 94.
    Rhee CM, Kalantar-Zadeh K, Ravel V, et al. Thyroid status and death risk in US veterans with chronic kidney disease. Mayo Clin Proc. 2018;93(5):573–85.PubMedCrossRefGoogle Scholar
  95. 95.
    You AS, Sim JJ, Kovesdy CP, Streja E, Nguyen DV, Brent GA, Kalantar-Zadeh K, Rhee CM. Association of thyroid status prior to transition to end-stage renal disease with early dialysis mortality. Abstract submitted to the 2018 International Congress of Nutritional and Metabolism.Google Scholar
  96. 96.
    Rhee CM, Chen Y, You AS, et al. Thyroid status, quality of life, and mental health in patients on hemodialysis. Clin J Am Soc Nephrol : CJASN. 2017;12(8):1274–83.PubMedCrossRefGoogle Scholar
  97. 97.
    Vigario Pdos S, Vaisman F, Coeli CM, et al. Inadequate levothyroxine replacement for primary hypothyroidism is associated with poor health-related quality of life-a Brazilian multicentre study. Endocrine. 2013;44(2):434–40.PubMedCrossRefGoogle Scholar
  98. 98.
    Kalantar-Zadeh K, Unruh M. Health related quality of life in patients with chronic kidney disease. Int Urol Nephrol. 2005;37(2):367–78.PubMedCrossRefGoogle Scholar
  99. 99.
    United States Renal Data System. USRDS 2012 Annual Data Report: Atlas of End-Stage Renal Disease in the United States. Bethesda, MD; 2012.Google Scholar
  100. 100.
    Biondi B, Fazio S, Palmieri EA, et al. Left ventricular diastolic dysfunction in patients with subclinical hypothyroidism. J Clin Endocrinol Metab. 1999;84(6):2064–7.PubMedCrossRefGoogle Scholar
  101. 101.
    Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86(3):1110–5.PubMedCrossRefGoogle Scholar
  102. 102.
    Owen PJ, Rajiv C, Vinereanu D, Mathew T, Fraser AG, Lazarus JH. Subclinical hypothyroidism, arterial stiffness, and myocardial reserve. J Clin Endocrinol Metab. 2006;91(6):2126–32.PubMedCrossRefGoogle Scholar
  103. 103.
    Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92(5):1715–23.PubMedCrossRefGoogle Scholar
  104. 104.
    Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172(10):811–7.PubMedCrossRefGoogle Scholar
  105. 105.
    Wartofsky L. Levothyroxine: therapeutic use and regulatory issues related to bioequivalence. Expert Opin Pharmacother. 2002;3(6):727–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  • Connie M. Rhee
    • 1
    Email author
  • Gregory A. Brent
    • 2
  • Kamyar Kalantar-Zadeh
    • 3
  1. 1.Division of Nephrology and Hypertension, Departments of Medicine and Public Health, University of California Irvine School of MedicineOrangeUSA
  2. 2.Division of Endocrinology, Diabetes, and Hypertension, Departments of Medicine and PhysiologyDavid Geffen School of Medicine at UCLALos AngelesUSA
  3. 3.Division of Nephrology and Hypertension, Departments of Medicine, Pediatrics, Public Health, and Nursing Sciences, University of California Irvine School of MedicineOrangeUSA

Personalised recommendations